Moderna Therapeutics, a developer messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has expanded their headquarters to Technology Square in Cambridge, Mass. Moderna will have up to 100 full-time employees at two locations by the end of 2013.
"With this facility, we intend to deliver on the promise of messenger RNA therapeutics by developing transformative new medicines for a wide range of diseases, including many that are untreatable today," said Stephane Bancel, president and founding CEO of Moderna.
The new site will be the center of Moderna's R&D and provide a significant increase in laboratory space for formulation, screening and both in-vivo and in-vitro studies. The facility houses administrative and corporate needs as well as IT specialists and is equipped with state-of-the-art technology to enable virtual collaboration and cloud-based computing. Moderna's previous Cambridge headquarters will continue to serve as an additional site for manufacturing and quality.